Anti-TNFRSF10B Antibody (MOM-18203)
|Recombinant Anti-Human TNFRSF10B Antibody
- Product Overview
- Recombinant Human Antibody is specific to Human DR5, expressed in Chinese Hamster Ovary cells(CHO)
- Suitable for use in IF, IP, Neut, FuncS, ELISA, FC, IHC and most other immunological methods.
- Specific Activity
- Tested positive against native antigen.
- Protein Construction
- Immunoglobulin G1, anti-(human cytokine receptor DR5 (death receptor 5)) (human monoclonal XG1-048 v w heavy chain), disulfide with human monoclonal XG1-048 light chain, dimer
- Predicted N terminal
- H chain: QLPGKGL; L Chain: EIVLTQS
- >95.0% as determined by analysis by SDS-PAGE.
- Store at -20°C. Avoid multiple freeze/thaw cycles.
- Antigen Description
- Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.
- TRAIL binding; protein binding; receptor activity;
- TNFRSF10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor superfamily member 10B; CD262; DR5; KILLER; TRAIL R2; TRICK2A; TRICKB; Fas-like protein; death receptor 5; cytotoxic TRAIL receptor-2; apoptosis inducing receptor TRAIL-R2; apoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; death domain containing receptor for TRAIL/Apo-2L; tumor necrosis factor receptor-like protein ZTNFR9; p53-regulated DNA damage-inducible cell death receptor(killer); TRICK2; ZTNFR9; TRAILR2; TRICK2B; TRAIL-R2; KILLER/DR5;
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.